Key facts
- This page summarizes Kevin Koch's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2025, 19:42.
Kevin Koch - 12 Aug 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- EWTX
- Reported as of
- 12 Aug 2025
- Net transaction value
- -$106,764
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2025, 19:42:14 UTC
- Prior SEC filing
- 07 May 2025
- Next SEC filing
- 14 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/John R. Moore Attorney-in-Fact for Kevin Koch
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin Koch filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 14 Aug 2025.
Change
- Previous filing in this sequence was filed on 07 May 2025.
- Current net transaction value: -$106,764.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001185829
Primary reporting owner
KOCH KEVIN
- Relationship
- President and CEO, Director
- Address
- C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
- Signature
- /s/John R. Moore Attorney-in-Fact for Kevin Koch
- Signature date
- 14 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EWTX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +17,968
- Change %
- +87%
- Price
- $0.000000
- Shares after
- 38,587
- Date
- 12 Aug 2025
- Ownership
- Direct
EWTX
transaction
Common Stock
Sale
- Transaction value
- $106,764
- Shares
- -7,972
- Change %
- -21%
- Price
- $13.39
- Shares after
- 30,615
- Date
- 12 Aug 2025
- Ownership
- Direct
- Footnotes
- F1, F2
EWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 259,554
- Date
- 12 Aug 2025
- Ownership
- KTK Family Enterprise, LLC
EWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 26,410
- Date
- 12 Aug 2025
- Ownership
- Adrienne R. Koch Heritage Trust
EWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 26,410
- Date
- 12 Aug 2025
- Ownership
- Matthew K. Koch Heritage Trust
EWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 26,410
- Date
- 12 Aug 2025
- Ownership
- Nicole M. Soldow Heritage Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EWTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -17,968
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 53,907
- Date
- 12 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,968
- Exercise price
- $0.000000
- Footnotes
- F3
EWTX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +87,500
- Change %
- Price
- $0.000000
- Shares after
- 87,500
- Date
- 12 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,500
- Exercise price
- $0.000000
- Footnotes
- F4
EWTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +525,000
- Change %
- Price
- $0.000000
- Shares after
- 525,000
- Date
- 12 Aug 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 525,000
- Exercise price
- $13.39
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
Footnote F2
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Footnote F4
Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
Footnote F5
1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
SEC remarks
In previous Forms 4, a duplicate 26,410 shares held indirectly were reported in error.